Get started

Financials · NSPR

InspireMD Inc. (NSPR) financials

For the twelve months ended Jun 30, 2026, InspireMD Inc. reported $10.84M of revenue and -$52.48M of net income.

Revenue, TTM
$10.84M
Revenue growth, YoY
+53.4%
Net income, TTM
-$52.48M
Net margin
-484.1%
Free cash flow, TTM
-$42.46M
Cash
$15.15M
P/S
3.03
Market cap
$32.8M
Annual revenue$8.98M
FY2016FY2025
Annual net income-$48.79M
FY2016FY2025
Annual free cash flow-$36.77M
FY2016FY2025

NSPR revenue and earnings growth

NSPR revenueQ2 2026$1.77M

Quarter YoY
-0.4%
QoQ
-47.9%
FY YoY
+28.1%
5Y CAGR
+29.3%
10Y CAGR
+14.5%

NSPR revenue was $1.77M in fiscal Q2 2026 (ended Jun 30, 2026), down 0.4% from a year earlier and down 47.9% from the prior quarter. For the full fiscal 2025 it was $8.98M, up 28.1% from fiscal 2024. Compound annual growth was +29.3% over 5 years and +14.5% over 10 years. It rose in 8 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

NSPR net incomeQ2 2026-$14.32M

NSPR net income was -$14.32M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$13.15M a year earlier. For the full fiscal 2025 it was -$48.79M, compared with -$32.01M in fiscal 2024.

NSPR EPSQ2 2026-$0.17

NSPR diluted EPS was -$0.17 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.76.

NSPR free cash flowQ2 2026-$11.22M

NSPR free cash flow was -$11.22M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$8.91M a year earlier. For the full fiscal 2025 it was -$36.77M, compared with -$23.27M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$8.98M$7.01M$6.21M$5.17M$4.50M$2.48M$3.72M$3.60M$2.76M$1.89M
Cost of revenue$6.33M$5.50M$4.40M$4.05M$3.74M$2.40M$2.96M$2.61M$2.18M$1.79M
Gross profit$2.65M$1.51M$1.81M$1.12M$754.0K$83.0K$756.0K$995.0K$585.0K$102.0K
Research and development$15.00M$13.63M$7.98M$7.81M$5.16M$2.23M$2.95M$1.53M$1.28M$1.29M
Selling, general and admin$20.71M$15.31M$11.10M$8.36M$7.41M$6.13M$5.22M$4.83M$5.18M$5.00M
Operating income-$49.61M-$33.50M-$21.14M-$18.71M-$14.72M-$10.38M-$9.82M-$7.61M-$8.23M-$7.65M
Interest expense--------$119.0K$721.0K
Pre-tax income-$48.72M-$31.95M-$19.85M-$18.46M-$14.87M-$10.54M-$10.02M-$7.24M-$8.41M-$8.46M
Income tax$63.0K$59.0K$65.0K$28.0K$45.0K$4.0K$24.0K-$27.0K$1.0K
Net income-$48.79M-$32.01M-$19.92M-$18.49M-$14.92M-$10.54M-$10.04M-$7.24M-$8.44M-$8.46M
EPS, basic-$0.76-$0.76-$0.82-$2.35-$2.03-$6.97-$72.00-$250.05-$26235.00-$155790.00
EPS, diluted-$0.76-$0.76-$0.82-$2.35-$2.03-$6.97-$72.00-$250.05-$26235.00-$155790.00
Diluted shares64.3M41.9M24.3M7.9M7.3M1.5M139,330.93330,769.267496.61354.309

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$8.94M$18.92M$9.64M$4.63M$12.00M$12.64M$5.51M$9.38M$3.71M$7.52M
Short-term investments$45.27M$15.72M$29.38M-------
Receivables$2.17M$1.57M$1.80M$1.03M$1.22M$476.0K$823.0K$716.0K$643.0K$356.0K
Inventory$3.40M$2.57M$2.11M$1.62M$1.14M$1.42M$1.24M$1.13M$533.0K$500.0K
Current assets$61.47M$40.52M$44.16M$21.33M$37.09M$15.34M$7.81M$11.42M$5.16M$8.63M
Total assets$69.40M$46.81M$47.64M$24.65M$39.71M$17.78M$9.88M$12.29M$6.11M$9.41M
Current liabilities$10.71M$7.68M$6.02M$5.07M$4.35M$3.71M$3.12M$2.92M$2.48M$4.78M
Short-term debt---------$2.68M
Total liabilities$14.20M$10.72M$8.14M$7.26M$6.18M$5.61M$4.50M$3.52M$3.11M$5.37M
Shareholders' equity$55.20M$36.09M$39.50M$17.39M$33.53M$12.16M$5.38M$8.76M$2.73M$4.04M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$35.10M-$21.87M-$16.38M-$15.54M-$13.21M-$9.08M-$9.81M-$7.61M-$8.13M-$7.50M
Capital expenditures$1.66M$1.40M$381.0K$473.0K$344.0K$88.0K$284.0K$67.0K$258.0K$49.0K
Free cash flow-$36.77M-$23.27M-$16.76M-$16.02M-$13.55M-$9.17M-$10.09M-$7.67M-$8.39M-$7.54M
Investing cash flow-$30.56M$12.64M-$16.09M$8.44M-$22.46M-$187.0K-$387.0K-$44.0K-$318.0K$70.0K
Financing cash flow$55.57M$18.45M$37.53M-$140.0K$35.03M$16.39M$6.33M$13.37M$4.63M$11.70M
Stock-based compensation$12.33M$10.14M$4.49M$2.35M$1.58M$606.0K$325.0K$70.0K$672.0K$978.0K
Depreciation and amortization$476.00M$280.00M$232.00M$188.00M$161.0K$151.0K$158.0K$152.0K$153.0K$142.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY28.1%13.0%20.0%15.0%80.9%-33.2%3.3%30.4%45.8%-18.0%
Gross margin29.5%21.5%29.1%21.6%16.8%3.3%20.3%27.6%21.2%5.4%
Operating margin-552.6%-478.0%-340.7%-361.9%-327.4%-417.7%-263.8%-211.4%-298.2%-403.8%
Net margin-543.3%-456.6%-321.0%-357.6%-331.9%-424.3%-269.8%-201.1%-305.6%-446.7%
Free cash flow margin-409.5%-332.0%-270.1%-309.7%-301.5%-369.0%-271.3%-213.1%-303.8%-398.3%
Return on equity-88.4%-88.7%-50.4%-106.3%-44.5%-86.7%-186.5%-82.6%-309.4%-209.2%
Return on assets-70.3%-68.4%-41.8%-75.0%-37.6%-59.3%-101.6%-58.9%-138.2%-89.9%
Current ratio5.745.287.344.218.534.142.513.912.081.81

Source: XBRL data InspireMD Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Nov 9, 2015; 1-for-35, first reported Feb 13, 2018; 1-for-50, first reported May 13, 2019; 1-for-15, first reported May 10, 2021.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

NSPR peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
NSPR$10.84M+53.4%-$52.48M-484.1%$32.8M
BSX$21.07B+8.9%$3.50B16.6%$63.81B
MDT$37.54B+9.8%$5.24B14.0%$131.48B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
EW$6.67B+13.4%$1.02B15.3%$60.21B
PEN$1.56B+17.0%$157.02M10.1%$12.69B
SYK$26.30B+7.9%$3.62B13.8%$124.00B

NSPR FAQ

8 questions
  • What is NSPR revenue?
    InspireMD Inc. (NSPR) reported $10.84M of revenue for the twelve months ended Jun 30, 2026. That is up 53.4% from the year before. Revenue for fiscal 2025 was $8.98M.
  • Is NSPR profitable?
    No. InspireMD Inc. reported a net loss of $52.48M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does NSPR have?
    InspireMD Inc. reported $15.15M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is NSPR revenue growing?
    InspireMD Inc.'s revenue changed +28.1% in fiscal 2025, to $8.98M. Its compound annual growth rate was +29.3% over 5 years and +14.5% over 10 years.
  • What is NSPR gross margin?
    InspireMD Inc.'s gross profit was $1.96M on $10.84M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 18.1%.
  • What is NSPR free cash flow?
    InspireMD Inc. generated -$42.46M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$41.21M less capital expenditures.
  • When did NSPR last report financial results?
    The latest statements here come from InspireMD Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.
  • Where does this NSPR financial data come from?
    Quantisnow builds these statements from the structured XBRL data InspireMD Inc. files with the SEC. It is provided for information only and is not investment advice.